Clinical Trials Logo

Haemophilia B With Inhibitors clinical trials

View clinical trials related to Haemophilia B With Inhibitors.

Filter by:

NCT ID: NCT00703911 Completed - Clinical trials for Congenital Bleeding Disorder

Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors

ONE
Start date: March 2008
Phase: N/A
Study type: Observational

This study was conducted in Africa, Europe, the Middle-East and South America. The primary objective of this registry was to observe the use of single dose and multi-dose use of activated recombinant human factor VII and to compare short-term outcomes, including effectiveness, safety, quality of life and treatment satisfaction with the approved treatments.

NCT ID: NCT00571584 Completed - Clinical trials for Congenital Bleeding Disorder

High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors

Start date: November 2002
Phase: Phase 4
Study type: Interventional

This trial is conducted in Europe. The aim of this trial is to evaluate the efficacy and safety of two dose schedules of activated recombinant human factor VII in treatment of joint bleeds in haemophilia patients with inhibitors.

NCT ID: NCT00108797 Completed - Clinical trials for Congenital Bleeding Disorder

Trial of NovoSeven® in Haemophilia - Joint Bleeds

Start date: September 2001
Phase: Phase 4
Study type: Interventional

This trial is conducted in the United States of America (USA). This study compares the effectiveness and safety of NovoSeven® to FEIBA (FEIBA VH) in haemophilia patients with inhibitors being treated for joint bleeds.

NCT ID: NCT00108758 Completed - Clinical trials for Congenital Bleeding Disorder

Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

Start date: March 2004
Phase: Phase 2
Study type: Interventional

This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA). The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven® in haemophilia A and B patients with inhibitors.